Yuan Jiang and his team have just opened a new door in the fight against progressive multiple sclerosis—one that might lead doctors and researchers not to the laboratory bench, but to the pharmacy shelf. A new study published in the Journal of Neuroinflammation reveals that 13 existing drugs originally developed for other diseases could potentially be repurposed to treat the most debilitating form of MS, where patients experience relentless neurological decline.
Progressive MS represents one of medicine's toughest challenges. Unlike relapsing-remitting forms of the disease, which respond to established immunotherapies, progressive MS gradually worsens over time as nerve cells deteriorate and connections are lost. The urgency is real: patients and clinicians have long awaited better treatment options that specifically address disease progression and the underlying neurodegeneration driving it forward.
Jiang, affiliated with the Department of Medicine in Huddinge and the Department of Clinical Neuroscience in Solna, led a study that took an ambitious approach: rather than hunting for completely new drugs from scratch, the researchers used multi-omics integration—a technique that combines genetic, protein, and molecular data—to identify promising targets hiding in plain sight. They started by analyzing 48 genetically supported proteins, then narrowed their focus to 14 with genuine therapeutic potential. The breakthrough came when they identified 13 non-MS drugs already in use worldwide that could potentially be redirected toward progressive MS treatment.
But the real insight emerged when Jiang's team drilled deeper. From their analysis, six key proteins emerged as particularly significant—proteins that offered not just drug targets, but genuine biological understanding of how progressive MS develops and progresses. This distinction matters enormously. Understanding the mechanisms behind disease progression doesn't just identify which drugs to try; it fundamentally reshapes how researchers think about the disease itself.
The implications ripple across the medical landscape. Professionals in neurology, neuroimmunology, genetics, drug development, and precision medicine now have a roadmap: existing drugs already approved for safety and tested in human populations could move directly into MS trials rather than waiting years for new compounds to be developed and validated. Some of these drugs already have established dosing protocols, known side effect profiles, and manufacturing infrastructure. For patients, this compressed timeline could mean faster access to new treatment options.
Drug repurposing has proven successful across medicine—existing therapies finding new life against unexpected diseases. In MS specifically, where neurodegeneration is progressive and relentless, any acceleration in delivering new options to patients matters. The six identified proteins offer researchers something equally valuable: biological clues that could guide the next generation of targeted treatments, whether those come from repurposed drugs or novel therapies yet to be discovered.
What happens next depends on validation and clinical trials. But this study has handed the field something concrete to work with: a prioritized list of candidates, grounded in genetic evidence and multi-omics analysis, ready for the next phase of investigation. For patients with progressive MS and the neurologists treating them, that represents hope built on science.